Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease
about
The promise of neuroprotective agents in Parkinson's diseaseFDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp and protect against proteotoxicityCan coffee consumption lower the risk of Alzheimer's disease and Parkinson's disease? A literature review.Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2.Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease.Pathophysiological roles for purines: adenosine, caffeine and urate.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease modelsAdenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's diseaseProtection of dopaminergic cells by urate requires its accumulation in astrocytesNeuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.The emerging role of nutrition in Parkinson's disease.Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.Rational drug discovery design approaches for treating Parkinson's disease.Health benefits of methylxanthines in neurodegenerative diseases.Autophagy inhibition by caffeine increases toxicity of methamphetamine in SH-SY5Y neuroblastoma cell line.The neuroprotective effects of caffeine in neurodegenerative diseases.Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson's disease.The MPTP Story.Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage.Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats.Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.The role of calcium channel blockers and resveratrol in the prevention of paraquat-induced parkinsonism in Drosophila melanogaster: a locomotor analysis.Ryanodine Receptors in Autophagy: Implications for Neurodegenerative Diseases?Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic Caenorhabditis elegans.Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive RolePhenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation
P2860
Q21129436-05357946-A815-488F-B481-C035B82656F6Q28478041-CBB23C48-D385-4D01-ADDE-F58E314853CDQ33645947-6A42A881-06DC-4D8D-AF8C-7858B6EB6199Q33782664-910AA357-1E4B-44DD-A0CE-0B68C55DC70DQ34359390-100420D2-F508-41FE-A797-8BBCA9D22927Q35008049-29A83892-8C9A-467D-B457-A6D6E027E8F8Q35489240-27FDF9BE-D166-4E91-821A-0398A647B934Q35529695-F065AE80-1C90-46E5-999C-338C29727E85Q35799088-629AF9FD-84A0-48C2-84B5-C326B1D37BDBQ35830757-B29F7E52-3032-4BFC-82E7-E7B1AF1A98AAQ36223240-CE2B4A59-18BF-4871-98C9-7982CFB5BAA8Q36723079-4272A92A-67F5-441E-A596-130F08569F55Q37622710-AB34C95E-8FE0-4400-AA6A-B0EB96017349Q37863150-CEEBBD3E-4FC2-4675-A471-BA96EADA0E4CQ38199744-DFDD9023-F870-44EC-8FFE-A9ADEC57A8B2Q38520864-5429B68C-B883-483C-A762-19099CAD446DQ38772021-F9166B09-DB66-4736-9325-90BCFEC3EAE0Q38919961-6B6A1F6D-9206-48D7-8572-1E043D5DFBC1Q39186884-2FE848FF-651E-4AD8-9CB1-63B9FBA0D89BQ40358428-A5B2B727-F834-4320-B9D2-A494F0068574Q40462891-7D66EFF7-1B96-4CE6-91A0-62012872D60FQ41825283-9C02AEFA-5728-47AF-9954-BF81037DE5F6Q47387315-F69C0B6F-0F17-498E-8F41-1E4B20F9D154Q48140668-A422FE3E-511F-481F-9D5C-29F747A89885Q49336936-CF6D713B-3D37-4501-BAD1-E88CBDF03020Q50125651-2632BB30-6F52-4CD7-BEA9-8C0F5A85FD84Q52719394-9C780EBC-80DC-4247-8312-3FE605C6A695Q54974646-C41BC85B-5A6F-44B7-8C0C-35B92A1B79D3Q54975826-61D5AA17-7013-436E-8610-2045B837F957Q56839380-AC5915CB-9951-486D-A15D-C405C6E9BCBDQ58122620-CC79D4C9-508D-498D-B5BA-2AECAA0EBE48
P2860
Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@ast
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@en
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@nl
type
label
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@ast
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@en
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@nl
prefLabel
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@ast
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@en
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@nl
P2093
P2860
P1433
P1476
Neuroprotection by caffeine: t ...... P model of Parkinson's disease
@en
P2093
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2010.02.020
P407
P577
2010-05-05T00:00:00Z